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Objectives. To compare percutaneousmitral valve repair (PMVR)with optimalmedical therapy (OMT) in patients with heart failure
(HF) and severe functional mitral regurgitation (FMR). Background. Many patients with HF and FMR are not suitable for surgical
valve replacement and remain symptomatic despitemaximalOMT. PMVRhas recently emerged as an alternative solution.Methods.
We performed a systematic review and a meta-analysis to address this question. Cochrane CENTRAL, MEDLINE, and Scopus
were searched for randomized (RCT) and nonrandomized studies comparing PMVR with OMT in patients with HF and FMR.
Primary endpointwas all-causemidtermmortality (at 1 and 2 years). Secondary endpointswere 30-daymortality and cardiovascular
mortality and HF hospitalizations, at maximum follow-up. Studies including mixed cohort of degenerative and functional MR
were allowed initially but were excluded in a secondary sensitivity analysis for each of the study’s end points. This meta-analysis
was performed following the publication of two RCTs (MITRA-FR and COAPT). Results. Eight studies (six observational, two
RCTs) comprising 3,009 patients were included in the meta-analysis. In comparison with OMT, PMVR significantly reduced 1-year
mortality (RR: 0.70 [0.56, 0.87]; p=0.002; I2=47.6%), 2-year mortality (RR: 0.63 [0.55, 0.73]; p<0.001; I2=0%), and cardiovascular
mortality (RR: 0.32 [0.23, 0.44]; p<0.001; I2=0%). No significant difference between PMVR+OMT and OMT was noted in HF
hospitalization (HR: 0.69 [0.40, 1.20]; p=0.19; I2=85%) and 30-day mortality (RR: 1.13 [0.68, 1.87]; p=0.16; I2=0%). Conclusions. In
comparisonwithOMT, PMVR significantly reduces 1-yearmortality, 2-yearmortality, and cardiovascularmortality in patients with
HF and severe MR.
1. Introduction
Functional mitral regurgitation (FMR) is seen in most
patients with heart failure (HF) and is classified as moderate
to severe in 30% of them [1, 2]. The presence of signifi-
cant FMR in patients with left ventricular dysfunction is
associated with adverse outcomes, including death and fre-
quent hospitalization for HF [3–5]. Optimal medical therapy
(OMT) may provide symptomatic relief in some patients
but many remain symptomatic despite maximal OMT [6].
Contemporary surgical mitral repair and replacement oper-
ations are performed with excellent short-term outcomes.
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However, only a minority of patients with FMR are referred
for isolated mitral valve repair or replacement due to the
lack of compelling data proving the long-term efficacy of
surgical interventions for FMR [7, 8]. The emergence of
percutaneous mitral valve repair (PMVR) was accompanied
with a wealth of clinical investigations aiming to assess
its value in addressing the unmet need of treating severe
symptomatic FMR in HF patients [9, 10]. Several studies
have demonstrated the safety and efficacy of the MitraClip
(Abbott Vascular, Lake Bluff, Illinois) in patients with FMR
[11–13]. However, only a few studies compared the outcomes
of PMVR with MitraClip to OMT. We hence performed
a systematic review and a meta-analysis to address these
questions.
2. Methods
This meta-analysis was performed in accordance with the
Preferred Reporting Items for Systematic review and Meta-
Analyses (PRISMA) guidelines and the American Heart
Association guidelines [14]. We utilized the relevant key-
words “MitraClip”, “percutaneous mitral valve repair”, and
“transcatheter mitral valve repair” in conjunction withMeSH
terms to search MEDLINE, Cochrane, CENTRAL, and Sco-
pus databases. The search was conducted from inception of
the databases to September 25, 2018 (Supplemental Table 1).
A supplementary searchwas done using citation chasing from
relevant articles and hand searching of journals. Sources for
the supplementary search included bibliographies of relevant
reviews, editorials from major medical journals, websites
of major journals, and conference proceedings for indexed
abstracts. No language restrictions were placed.
All retrieved articles were transferred to EndNote X7
(Clarivate Analytics, Pennsylvania, United States) and dupli-
cates were identified and removed. The remaining articles
were screened by 2 reviewers (MUL and MSU) based on
title and abstract. A third reviewer (MSK) was consulted
to resolve discrepancies. Articles were selected based on
the following eligibility criteria: (I) PMVR was compared
with OMT in adult population (age ≥18 years) and at
least 70% of the patients had heart failure complicated by
functional MR. Study data were sought from the full texts
of the included articles. Data were abstracted on study
characteristics, baseline variables of patients, and outcomes
of interest. In case cohorts of patients overlapped between
studies, we included the study with the larger sample size in
the analysis. When available, data from propensity-matched
cohorts was preferred over unmatched data. The primary
outcome was midterm all-cause mortality measured at 1-
and 2-year intervals. The secondary outcomes were 30-day
mortality, HF related hospitalizations, and cardiovascular
death.
Risk of bias was assessed by two independent reviewers
(MSU and MAAK), and a third reviewer was consulted to
solve disagreements. Cochrane Collaboration’s risk of bias 2.0
(ROB 2.0) tool was used to ascertain the risk of bias of the
RCTs while the “Risk of Bias In Nonrandomized Studies-of
Interventions” (ROBINS-I) tool was used to assess the risk of
bias of observational studies.
Reviewmanager (v.5.3) andOpenMetaAnalyst were used
to perform the analysis. For the mortality outcomes, odd
ratio and 95% confidence intervals (CIs) were calculated
using raw, unadjusted data from each included study. For
HF hospitalization, the hazard ratios (HRs) provided by
the studies were converted to generic inverse variances and
standard errors and used as the effect size.TheORs/HRs were
pooled using a random-effects model because of anticipated
heterogeneity. Subgroup analysis according to type of study
(observational versus RCTs) was conducted, and the chi-
squared test was used to evaluate subgroup differences.
Leave-one-out sensitivity analysis was conducted for all
outcomes to assess if any single study disproportionately
influenced the results. In order to study a cohort exclusively
composed of patients with functional MR, we conducted a
sensitivity analysis by removing studies with both functional
MR and degenerative MR patients. Furthermore, we carried
out a cumulative meta-analysis on primary outcome to study
temporal trends. This chronological meta-analysis reveals if
there is a consistency in the results of consecutive studies
and indicates the point at which no further studies are
necessary because the results continually favor 1 intervention.
A secondary analysis was conducted to estimate the pooled
risk difference between the PMVR and OMT groups per
1000-patient years and subsequently calculate the Number
Needed to Treat (NNT) to prevent mortality. Heterogeneity
across studies was evaluated using the I2 index, and a value of
I2=25%-50% was considered mild, 50%-75% moderate, and
>75% severe. Visual inspection of the funnel plot and Egger’s
regression test were used to assess publication bias. A p value
of <0.05 was considered significant in all cases.
3. Results
The initial search revealed 4,379 potentially relevant articles.
After excluding duplicates and nonrelevant or incomplete
publications (abstracts), 8 primary studies including 3,009
patients (1,689 in the PMVR arm, and 1320 in the OMT arm)
were used in the synthetic analysis (Figure 1) [15–22].
3.1. Quality Assessment. All included observational studies
were of moderately good methodological quality (Supple-
mentary Tables 2 and 3). Five of the observational studies
used propensity-matched analysis. Although both included
RCTs had a robust methodology, there was a risk of bias due
to lack of allocation concealment and lack of blinding in these
studies.
3.2. Patient and Study Characteristics. The average age of
the included patients was 72 years, and 62% of them were
male. The average LVEF of the population was 33%, and
69% of them were classified as New-York-Heart-Association
class III or IV. More than half (53%) of the study population
had been diagnosed with coronary artery disease, and 48%
had a history of atrial fibrillation. Baseline characteristics are
outlined in Table 1. A summary of the inclusion criteria and
study characteristics are given in Table 2.
3.3. Meta-Analysis of 1-Year Mortality. Seven studies repre-
senting 2,854 patients reported all-cause mortality at 1 year
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Figure 1: Study flow chart.
[15, 16, 18–21, 23]. A meta-analysis of these studies showed
that PMVR significantly reduced 1-year all-cause mortality
in comparison with OMT (RR: 0.70 [0.56, 0.87]; p=0.002;
I2=47.6%) (Figure 2). Observational studies corroborated the
overall finding, showing significant change in relative risk
of 0.61 ([0.48, 0.78]; p<0.001; I2=26.3%). In contrast the
results from RCTs were nonsignificant (RR: 0.90 [0.66, 1.23];
p=0.51; I2=33.3%). However, the difference between the two
subgroups was nonsignificant (p interaction >0.05). Sensitiv-
ity analysis by removing studies including degenerative MR
patients did not significantly change the results (RR: 0.76
[0.59, 0.99]; p=0.043; I2=48.8%).
3.4.Meta-Analysis of 2-YearMortality. Four studies including
1,689 patients reported all-cause mortality rates at 2 years
[16, 19, 21, 23]. A meta-analysis of these studies showed
that PMVR was superior to OMT alone in reducing 2-year
mortality (RR: 0.63 [0.55, 0.73]; p<0.001; I2=0%) (Figure 3).
Both observational studies (RR: 0.63 [0.51, 0.76]; p<0.001;
I2=0%) and the single RCT (RR: 0.64 [0.52, 0.79]; p<0.001)
corroborated with the overall result (p interaction > 0.05).
Sensitivity analysis removing studies that included patients
with degenerativeMR did not significantly change the results
(RR: 0.47 [0.35, 0.62]; p<0.001; I2=0%).
3.5. Meta-Analysis of 30-Day Mortality. Six studies compris-
ing 2,064 patients reported all-cause mortality at 30 days
[15, 17, 18, 20–22]. Ameta-analysis of these studies showed no
significant difference between the PMVR and OMT groups
(RR: 1.13 [0.68, 1.87]; p=0.16; I2=0%) (Figure 4). Results
from both observational studies (RR: 1.0 [0.49, 2.02]; p=0.42;
I2=11.4%) and RCTs (RR: 1.72 [0.66, 4.36]; p=0.26; I2=0%)
6 Journal of Interventional Cardiology
Figure 2: Forest plot displaying the risk of 1-year mortality in the PMVR group compared to the OMT group.
Figure 3: Forest plot displaying the risk of 2-year mortality in the PMVR group compared to the OMT group.
were nonsignificant (p interaction >0.05). Sensitivity analysis
by removing studies comprising patients with degenerative
MR did not significantly change the results (RR: 1.38 [0.62,
3.07]; p=0.43; I2=0%).
3.6. Meta-Analysis of Cardiovascular Mortality. Four studies
(representing 1,236 patients) reported cardiovascular mortal-
ity [15, 17, 20, 21]. During a mean follow-up of 1.54 years,
PMVR significantly reduced cardiovascular mortality in
comparison toOMT (RR: 0.53 [0.31, 0.91]; p=0.021; I2=85.6%)
(Figure 5). Pooled observational studies also showed signif-
icant reduction in cardiovascular mortality (RR: 0.32 [0.23,
0.44]; p<0.001; I2=0%). Pooled RCTs, on the other hand,
did not show significant reduction (RR: 0.81 [0.50, 1.31];
p=0.38; I2=71.5%) (p interaction < 0.05). The results became
nonsignificant (RR: 0.65 [0.38, 1.09]; p=0.10; I2=76.7%) upon
removing studies, which included patients with degenerative
FMR.
3.7. Meta-Analysis of HFHospitalizations. Three studies (rep-
resenting 1,038 patients) reported HF hospitalization at a
mean follow-up of 1.64 years [20, 21, 23]. None of the
studies included patients with degenerativeMR.Therewas no
significant difference in the incidence of HF hospitalization
between patients treated with PMVR + OMT versus those
who were treated with OMT alone (HR: 0.69 [0.40, 1.20];
p=0.19; I2=85%) (Figure 6). The difference between results
from the observational study (HR: 0.54 [0.30, 0.97]; p=0.04)
and RCTs (HR: 0.76 [0.36, 1.63]; p=0.48; I2=92%) was
nonsignificant (p>0.05).
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Figure 4: Meta-analysis displaying the risk of 30-day mortality in the PMVR group compared to the OMT group.
Figure 5: Forest plot displaying the risk of cardiovascular mortality in the PMVR group compared to the OMT group.
3.8. Pooled Risk Difference and Number Needed to Treat.
The risk difference for all-cause mortality was -61.3 events
per 1000-patient years and a Number Needed to Treat of
nine to prevent one death per year. The risk difference for
cardiovascular mortality was -53.7 events per 1000-patient
years, with a Number Needed to Treat of five to prevent one
cardiovascular death per year (Supplementary Table 4).
3.9. Leave-One-Out Meta-Analysis. The results for 30-day,
1-year, and 2-year mortality were robust, with no single
study having a disproportionate effect on the results (Supple-
mentary Figures 1-3). The cardiovascular mortality outcome
became nonsignificant upon removal of all studies except one
(Obadia, 2018) (Supplementary Figure 4).
3.10. Cumulative Meta-Analysis. A temporal trend towards
higher mortality with PMVR (higher RRs) was seen for
the 30-day mortality outcome. Lack of consistency for this
outcome highlights the uncertainty of current evidence. For
1-year, 2-year, and cardiovascularmortality, no clear temporal
shift in the results was seen (Supplementary Figures 5-8).
3.11. Publication Bias. The funnel plot (Supplementary Figure
9) suggested presence of publication bias. The vacant right,
lower quadrant suggested that missing studies would have
been of small size and could have possibly shown increased
mortality with PMVR. Presence of publication bias was
confirmed by Eggers regression test (p=0.009).
4. Discussion
This meta-analysis of more than 3000 patients with HF and
severe MR shows that PMVR significantly reduces midterm
all-cause and cardiovascular mortality compared with OMT
8 Journal of Interventional Cardiology
Figure 6: Forest plot displaying the incidence of heart failure hospitalization in the PMVR group compared to the OMT group.
alone. However, HF hospitalizations and 30-day mortality
were not significantly different between the two groups.
A previous meta-analysis has shown a similar reduction
in all-cause mortality but also showed a reduction in HF
hospitalizations with PMVR [23]. Nonetheless, this study
was conducted prior to the publication of two recent RCTs
(MITRA-FR and COAPT) [20, 21]. Our updated meta-
analysis significantly enhances the evidence from the previ-
ous one, with an additional 888 patients included from one
observational and two RCTs.
Functional mitral regurgitation results from left ven-
tricular dilation and/or regional wall dyskinesis leading to
dislocation of the papillary muscles and tethering of the
leaflets. The differential negative impact of FMR on patient’s
symptomatology, progressive remodeling, and long-term
outcomes of patients with HF has been long established
[24, 25]. However, the ideal treatment for patients with FMR
who remain symptomatic despite OMT has been an area of
intense debate. Surgical mitral valve repair or replacement
can successfully eliminate FMR, but neither intervention has
been shown to reduce themorbidity andmortality associated
with FMR [26, 27]. In addition, both approaches are asso-
ciated with significant early risk of death and postoperative
complications [27–29].The emergence of transcathetermitral
valve repair and replacements systems led to a plethora of
investigations assessing their utility specifically in patients
with FMR.
TheMitraClip system is the first PMVR system to become
commercially available. Although the MitraClip was initially
approved to treat degenerative (primary) mitral regurgita-
tion, many FMR patients were treated with the MitraClip
on an off-label basis [12, 13]. This has led to a substantial
body of evidence suggesting its safety and efficacy in this
challenging group of patients. Nonetheless, data comparing
PMVR to OMT remained limited. A previous meta-analysis
addressing the same question found beneficial effects for
PMVR in FMR patients but it only included observational
data [23]. In light of the recent publication of the first
landmark RCTs comparing OMT to PMVR, we sought to
perform an updated systematic review and a meta-analysis
to elucidate the best available evidence on the key question
of whether PMVR carries an incremental benefit over OMT
alone in patients with FMR.Our analysis revealed that PMVR
with the MitraClip decreased all-cause mortality by 30% at 1
year and by 37% at 2 years. While the 1-year mortality benefit
was mostly driven by observational data, the 2-year benefit
was corroborated in both observational studies and the single
RCT reporting 2-year mortality data. In addition, PMVRwas
associated with lower cardiovascular death and no excess
short-term mortality (at 30 days).
The findings of this meta-analysis raise several important
issues: (1) FMR is not a one-size-fits-all entity. This is best
illustrated by the striking differences between the COAPT
and MITRA-FR RCTs. Both of these trials were set to
address the same questions (utility of PMVR in FMR) and
reached strikingly different conclusions.This is likely because
each study enrolled a different subset of FMR patients.
The MITRA-FR trial enrolled patients with severely dilated
ventricles (no limit of left ventricular dimensions) and less
degrees of FMR (effective regurgitant orifice area>20 mm2,
regurgitant volume>30ml/beat), while COAPT only allowed
patients with less dilated ventricles (left ventricular diastolic
dimension <7 cm) and higher degrees of FMR (effective
regurgitant orifice area>30 mm2, regurgitant volume >45
ml/beat). In other words, COAPT likely selected patients in
whom the valvular disease was a large component of their
pathology while the valve disease was likely a pure bystander
in MITRA-FR. Hence, the substantial benefits of PMVR
observed in COAPT versus MITRA-FR are not surprising.
(2)The underlyingmechanism by which PMVR substantially
improved the outcomes of FMR patients remains a subject of
study. However, this meta-analysis might confirm the earlier
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observations suggesting a major role of PMVR-induced
reverse remodeling in improving long-term outcomes of
patients with FMR [12, 30]. (3) The mortality benefit that
was observed in our meta-analysis was robust but was more
consistent at 2 years (I2=0), suggesting that longer-term
follow-up might be needed in future PMVR investigations to
elucidate the potential benefit of the therapy in FMR patients.
(4) The lack of reduction in HF hospitalization should be
interpretedwith caution, due to the limited number of studies
reporting this endpoint and the potential subjectivity of this
endpoint itself.
Limitations: certain limitations must be taken into con-
sideration when interpreting the results of this study. Firstly,
the results of this analysis were partially based on observa-
tional studies, which are relatively more susceptible to bias
due to confounding. It must be noted, however, that we found
all observational studies to be of robust methodological
quality, with most employing propensity-matched analysis.
Second, the results for the cardiovascular mortality and
HF hospitalization outcomes had significant heterogeneity,
which could not be explained by subgroups according to
study design. Third, using RRs stratified according to time
(1 and 2 years) for the mortality outcome could potentially
lead to an overestimation of the effect size when compared
to time-to-event effect sizes. Fourth, variation in follow-up
time was not accounted for in the cardiovascular mortality
outcome, which could have led to some bias.
5. Conclusions
This meta-analysis suggests that, in comparison with OMT,
PMVR is not associated with excess 30-day mortality and
significantly reduce all-causemortality at 1 and 2 years. Given
the heterogeneity in the included FMR populations, further
studies are needed to confirm the results of this meta-analysis
and to identify to ideal candidate for PMVR.
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